Skip to content
PeptidesEncyclopedia
Informational, not medical advice

This is an approved / prescription medicine. Do not use without a prescription and medical supervision.

EMA-approvedaka Cerezyme

Imiglucerase — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Imiglucerase (also known as Cerezyme) is a peptide catalogued under Enzymes (Gaucher enzyme replacement). Neutral reference entry; EU status: EU-approved prescription medicine.

What is Imiglucerase?

Imiglucerase (brand name Cerezyme) is a recombinant human glucocerebrosidase (beta-glucosidase) approved as enzyme replacement therapy (ERT) for type 1 Gaucher disease; it was approved by the US FDA in 1994 and by the EMA in 1997.

It is supported by comparative clinical trial data and by large long-term registry cohorts (the ICGG Gaucher Registry), representing a high level of human clinical evidence spanning more than two decades of use.

It is not a peptide supplement but a licensed biologic prescription medicine administered under specialist supervision.

How does Imiglucerase work?

Imiglucerase is a mannose-terminated recombinant enzyme taken up by macrophage mannose receptors and delivered to lysosomes, where it hydrolyses accumulated glucocerebroside (glucosylceramide).

By clearing this stored lipid from Gaucher (lipid-laden) macrophages it reduces hepatosplenomegaly and improves the associated anaemia and thrombocytopenia.

What does the research say about Imiglucerase?

  • Enzyme therapy with mannose-terminated recombinant glucocerebrosidase improved haematologic and organ parameters comparably to the earlier placenta-derived enzyme. [1]
  • In 1028 registry patients, ERT reduced liver and spleen volume and corrected anaemia and thrombocytopenia over 2 to 5 years of treatment. [2]
  • Initial clinical improvements were largely sustained across 10 years of continued imiglucerase treatment. [4]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

  • [1] Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources — Grabowski GA et al., Annals of Internal Medicine 1995. (Comparative clinical trial)
  • [2] Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry — Weinreb NJ et al., The American Journal of Medicine 2002. (Registry cohort)
  • [3] The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease — Charrow J et al., Archives of Internal Medicine 2000. (Registry/observational)
  • [4] Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment — Weinreb NJ et al., Journal of Inherited Metabolic Disease 2013. (Long-term registry cohort)
  • [5] Therapeutic goals in the treatment of Gaucher disease — Pastores GM et al., Seminars in Hematology 2004. (Expert consensus/review)
  • [6] Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment — Weinreb NJ et al., Molecular Genetics and Metabolism 2021. (Long-term registry cohort)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

In clinical use imiglucerase is given as an intravenous infusion, most commonly every 2 weeks, with the dose individualised to disease severity and response.

This is context only and not a dosing recommendation; treatment is initiated and titrated by a metabolic specialist.

Side effects & safety profile

Infusion-associated reactions (flushing, urticaria, chest discomfort, fever) are the most common adverse events and are usually managed by slowing the infusion or premedication.

A minority of patients develop anti-imiglucerase IgG antibodies, which can be associated with hypersensitivity reactions, so antibody and clinical monitoring is advised.

As an intravenous enzyme it does not cross the blood-brain barrier, so neurological (type 2 and type 3) manifestations of Gaucher disease are not treated.

Stacking & combinations

It is a disease-specific enzyme replacement, not a performance or wellness agent, and is not intended to be combined with research peptides or supplements.

Finding Imiglucerase vendors

Finding Imiglucerase vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Sign in to review

Frequently asked questions

It is enzyme replacement therapy for type 1 Gaucher disease, replacing the deficient enzyme glucocerebrosidase to reduce liver and spleen enlargement and improve low blood counts.

References

  1. [1] Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources — Grabowski GA et al., Annals of Internal Medicine 1995. PMID: 7985893. View sourceStudy: Comparative clinical trialRecombinant imiglucerase matched the natural placenta-derived enzyme for haematologic and visceral response in type 1 Gaucher disease.
  2. [2] Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry — Weinreb NJ et al., The American Journal of Medicine 2002. PMID: 12133749. View sourceStudy: Registry cohortERT produced sustained reductions in liver and spleen volume and improvements in haemoglobin and platelet counts across a large registry population.
  3. [3] The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease — Charrow J et al., Archives of Internal Medicine 2000. PMID: 11025794. View sourceStudy: Registry/observationalCharacterised the clinical spectrum and burden of Gaucher disease in 1698 registry patients, framing treatment goals.
  4. [4] Long-term clinical outcomes in type 1 Gaucher disease following 10 years of imiglucerase treatment — Weinreb NJ et al., Journal of Inherited Metabolic Disease 2013. PMID: 22976765. View sourceStudy: Long-term registry cohortTen years of imiglucerase largely maintained the visceral and haematologic gains achieved in the early treatment years.
  5. [5] Therapeutic goals in the treatment of Gaucher disease — Pastores GM et al., Seminars in Hematology 2004. PMID: 15468045. View sourceStudy: Expert consensus/reviewDefined measurable therapeutic goals (anaemia, thrombocytopenia, organ volume, bone disease) for ERT in Gaucher disease.
  6. [6] Gaucher disease type 1 patients from the ICGG Gaucher Registry sustain initial clinical improvements during twenty years of imiglucerase treatment — Weinreb NJ et al., Molecular Genetics and Metabolism 2021. PMID: 33485799. View sourceStudy: Long-term registry cohortClinical improvements achieved early on imiglucerase were sustained over 20 years of continued therapy.
This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.